Candidate Selection
IND Enabling Studies
Phase 1
Phase 2
Phase 31
Upcoming
Milestones
(ROS1/TRKs/ALK)
Repotrectinib
ROS1+ advanced NSCLC in TKI-naïve patients
ROS1+ advanced NSCLC in TKI-pretreated patients
NTRK+ advanced solid tumors in TKI-naïve patients
NTRK+ advanced solid tumors in TKI-pretreated patients
TRIDENT-1
Registrational
cohorts
Current Phase
Phase 1
Upcoming Milestones
TRIDENT-1 Phase 1 enrollment ongoing2, Initiating registrational Phase 2 portion in 2H 2019
TRIDENT-1
Registrational
cohorts
TRIDENT-1 Phase 1 enrollment ongoing2, Initiating registrational Phase 2 portion in 2H 2019
ROS1+ or ALK+ non-NSCLC advanced solid tumors in TKI-naïve patients
Current Phase
Phase 1
Upcoming Milestones
Non-registrational cohort of TRIDENT-1
Non-registrational cohort of TRIDENT-1
Repotrectinib in pediatric advanced solid tumors
Current Phase
IND Enabling Studies
Upcoming Milestones
Initiating trial in 2H 2019
Initiating trial in 2H 2019
Repotrectinib + Tagrisso in EGFR mutated advanced NSCLC
Current Phase
IND Enabling Studies
Upcoming Milestones
Trial design in development
Trial design in development
(MET/CSF1R/SRC)
TPX-0022
Advanced solid tumor patients
Current Phase
Phase 1
Upcoming Milestones
Initiating trial in 2H 2019
Initiating trial in 2H 2019
(RET/SRC)3
TPX-0046
Advanced solid tumor patients
Current Phase
IND Enabling Studies
Upcoming Milestones
Initiating trial in 2H 2019
Initiating trial in 2H 2019
ALK-INHIBITOR
ALK+ NSCLC
Upcoming Milestones
Candidate selection in 2019
Candidate selection in 2019
- Not required for Phase 2 registrational clinical trials
- Phase 1 Portion of TRIDENT-1 ongoing with anticipated data read outs within 2019
- Including NSCLC, thyroid, and other solid tumors with abnormal RET gene